Belgium: According to the local press, a number of towns in the province of West Flanders plan to develop regulations to control and restrict the distribution of CBD shops in the region. Koksijde, De Panne and Nieuwpoort are planning to ban CBD shops and to open them near schools, amusement parks and other places frequented by minors. They will also consider limiting the total number of shops in a given area and plan to conduct background checks on shop owners based on the fact that selling CBD products makes it difficult to tackle drug problems.
France: Member of the National Assembly François-Michel Lambert has presented a draft law that would create a state monopoly on the production and sale of cannabis. The draft in its current version does not mention the CBD, although it sets a ceiling on THC concentration and restricts sales to state tobacco dealers. It is unclear what effect this would have on the sale of CBD consumer products, which may currently contain no traces of THC, while a pending appeal by the French Supreme Court in Case C-663/18 to the Court of Justice of the European Union is being decided.
France: The Council for Economic Analysis (Conseil d’analyse Économique), which informs government decisions on economic matters, has published a paper entitled “Cannabis: how to regain control? It recommends the strictly regulated legalisation of cannabis in a similar way to the draft law presented by Lambert, in order to limit access to cannabis for young adults, create jobs and increase tax revenues.
Latvia: A letter to the Latvian President claims that Parliament has restricted the cultivation of hemp for industrial purposes by adopting amendments to the law on the legal circulation of narcotic and psychotropic substances and medicines. The letter, signed by MP Andrejs Klementjevs, states that the cultivation of industrial hemp must be limited to the production of fibres and seeds, as such an interpretation is “explicitly mentioned by the UN Drugs Control Council”. However, the Ministry of Agriculture has submitted a proposal for a second reading to delete the reference to the purpose of cultivation, as the amendments adopted do not comply with the 1961 UN Convention on Narcotic Drugs, which Latvia has ratified.
Germany: The Health Committee of the German Bundestag, after discussing several legislative proposals, has passed the Federal Government’s draft bill “For more safety in the supply of medicines” (GSAV). According to the new law, the prices for medical cannabis – including CBD isolate and preparations containing CBD – are to be reduced. Once cannabis treatment is approved, it will also become easier to obtain a prescription for a new strain or product. The respective proposals of the Left Party and the Greens to improve patients’ access to medical cannabis by abolishing the current pre-approval requirements of health insurance companies were rejected.
Germany: The European Industrial Hemp Association (EIHA) has criticised the guidelines of the Federal Institute for Risk Assessment (BfR) on THC concentrations in food containing hemp from the year 2000. According to the EIHA, the limit values for THC in food are much stricter than for other harmful substances such as alcohol or nicotine, and the BfR’s risk assessment “does not meet scientific standards and urgently needs to be revised” to allow “competitive opportunities for the German hemp industry”. The EIHA refers to a study of the nova-Institut on the evaluation of the BfR guidelines, which emphasises the “systematic unequal treatment” of THC compared to other similarly effective substances and points out the “objectively wrong results” obtained by carrying out the risk assessment on sick people, who tend to react more strongly to THC than healthy people.
Luxembourg: The police, in cooperation with the Customs and Excise authorities and the public prosecutor’s office, investigated 34 CBD shops in Luxembourg, press reports. Random samples of CBD products were taken to determine whether they comply with the applicable legislation.
Portugal: Portuguese hemp growers have stated that they “will abandon the 2019 growing season because of continuing confusion between two governmental authorities over licensing”.
UK: The Church of England announced this week that it would lift a long-standing ban on medical cannabis to consider investment in the industry, according to press reports. It is believed that it will also include the possibility of investment in the hemp/CBD sector. The church has long banned investments in “sin industries”, although it considers pharmaceuticals acceptable.
EU: The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has published its European Drugs Report 2019: Trends and Developments, which examines the EU’s ‘drug supply and market, prevalence and trends in drug use, and drug-related harm and responses’. It focuses mainly on cannabis as a drug and discusses in more detail the increasing trend in synthetic cannabinoids. With regard to the booming market for CBD products, the report notes that the divergent views of national regulators on the legality of CBD-E liquids, flowers, oils and creams “raise problems for regulation at both EU and national level”, while the lack of an established testing standard for CBD products causes problems at the consumer level.
EU: The German Federal Office of Consumer Protection and Food Safety (BVL) reports that three EU Member States (Hungary, Ireland and Spain) have sent notifications of food products with CBD as unauthorised novel food ingredient to the portal of the EU’s Rapid Alert System for Food and Feed (RASFF).
Since 2017, the number of CBD shops in Italy has increased steadily. In 2018 alone, more than 300 such “Cannabis Light” stores opened nationwide and were pleased with growing customer numbers. After the rapid growth, the end of cannabidiol is now threatening after less than three years. Italy’s Supreme Court of Cassation ruled on Thursday that the sale of any part of the cannabis plant, including oil, leaves and resin, is illegal. Only the licensed cultivation of cannabis for medical purposes remains legal. The industry in Italy is accordingly shocked.
The Italian Minister of the Interior, Matteo Salvini, was delighted with the verdict. He had already announced this at an election meeting at the beginning of May:
“From today on I will go to war on Cannabis street by street, shop by shop, neighbour by neighbour, city by city, street by street”.
The controversial politician had sworn to close all CBD shops, because “drug consumption must be fought with all means”. However, Salvini has little interest in the fact that the sale and consumption of CBD and other cannabinoid products has very little to do with the consumption of “drugs”. He bases his argumentation on a ruling by the Supreme Health Council in Italy (CSS) last year. In it, the CSS stated that the dangerousness of CBD could not be excluded.
In Italy’s current government coalition, this is likely to become another controversial issue. The “five-star movement” involved in the government is even in favour of a complete legalisation of cannabis in general. So it can only be hoped that the last word has not yet been spoken on CBD. However, the current state of affairs means the end for CBD in Italy for the time being.
Bulgaria grants approval for various CBD products
Many EU member states are still discussing fiercely whether CBD products fall under the Novel Food Regulation or not. Other countries even believe that CBD products fall under the Narcotics Law.
The Ministry of Agriculture, Forestry and Food and the Food Safety Authority in Bulgaria have now officially approved various CBD products from Kannaway. Kannaway is a subsidiary of the US cannabis company Medical Marijuana. These products are known for their exceptionally high price and low concentration of active ingredients.
This certifies that the CBD products comply with the requirements of food legislation in Bulgaria. The same applies to the regulations of the European Food Safety Union. This means that the products are also officially approved for export to other countries.
However, all other member states are currently reluctant to issue official approvals. Many EU countries also do not want to confirm the legal conformity of CBD products. This makes the first official approval of CBD products in Bulgaria under consideration of the Novel Food Regulation really an absolute speciality and great news. According to the European Industrial Hemp Association (EIHA), hemp and its products are traditional foods. As a consequence, free sale in Bulgaria is also allowed.
Furthermore, it is said that Bulgaria wants to allow further products in the future, so that other manufacturers can bring their products to the market without any problems. The European Hemp Association is therefore also receiving official confirmation of its definition of hemp and hemp products. It is of course desirable that other countries now follow the example of Bulgaria.
According to the Ministry of Health in Luxembourg, a working group is currently analysing questions and taking the first steps towards preparation. This also includes “very close contact” with colleagues in the Netherlands and Canada, the government announced. At the end of May, Health Minister Etienne Schneider would fly to Canada “to get a first-hand impression”.
In the future, every adult in Luxembourg will be allowed to grow, buy, own and consume cannabis for personal use. All under strict conditions, of course, which still have to be determined. The Grand Duchy hopes that this will dry up the illegal market with its associated procurement criminality plus less health risks for consumers – by ensuring better quality of the substance. The revenues from “the national production and sales chain under state control” are to flow into addiction prevention.
The recent threats by Italian Interior Minister Matteo Salvini against CBD companies have been described by political insiders as empty.
Salvini does not have the authority to actively close CBD sellers – although his ministry has issued guidelines calling on the local authorities who do so to intensify and strengthen controls on retailers.
Similarly, his threat to overthrow the government – Salvini is also chairman of the political party Le Lega (Northern League), one of the main members of the governing coalition – was dampened as several authorities said that cannabis was simply not on the agenda.
The Federal Public Finance Service (FPS Finance) said the sale of CBD flowers was legal. They can also be sold by tobacco dealers and are taxed under the same name as “other smoking tobaccos”.
This means a duty of 31.5% of the retail selling price plus €48.3083 per kg fee plus 21% VAT.
This clarification is only a department note – i.e. the change is not yet final.
– Introduction to hemp (cannabis) and medicinal qualities
– Hemp-based ingredients in cosmetic & personal care products
– Applications in topical & skincare products
– Issues when using hemp-based ingredients
– Future outlook: what can we expect to see in this area?
If you want to book a seat in the audience, please contact
These limits apply exclusively to commercial cultivation and processing. These products can NOT be sold to an end customer.
There is not only the risk that users could be tested positive for THC in a drug test and even lose their drivinglicense or their job in case of doubt – as a dealer you violate applicable laws.
In some EU countries ( UK, IT, DE, FR… ) the zero tolerance policy on controlled substances is already in place and the other countries will follow, as no country will voluntarily raise the THC acceptance threshold again.
Zero tolerance means a non-detectability by the authorities. And this value is < = 0.0005%.
Any dealer who sells CBD products containing more than 0.0005% THC is liable to prosecution. And this is not an administrative offence, but a trade in narcotics.
Please bear this in mind when choosing your supplier.
“The EIHA (European Hemp Association) wishes to reaffirm its position on hemp extracts. Until the presentation of the EIHA, the limit line of the naturally occurring CBD content was not defined as a percentage of the CBD. The EIHA can confirm that the natural concentration of cannabidiol in hemp biomass commercially grown in the EU is between 1-5% on a dry weight basis.
We should note that indoor hemp varieties may contain much higher levels of naturally present CBD. Although we accept that the Novel Food Catalogue is not legally binding and serves only as a guide for food business operators (FBOs) and regulators, this should be seen as a standard position for all Member States.
FBOs can expect products with a natural concentration of cannabidiol to be placed on the market and thus comply with European directives. European guidelines on “high levels of consumption”, which also play an important role in distinguishing between traditional and novel foods, were already published in 2012 and any food placed on the market should comply with them.
The raw materials used by us ( so-called hemp dry matter ) originate from licensed cultivation areas of the EU and demonstrably contain up to 16.5% naturally present CBD supported by official analyses of state institutions.
Therefore, the new EU directive would only apply to products containing more than 16.5% CBD. All products in lower doses are therefore considered to conform to EU guidelines.
In addition (this is very important for distributors of CBD products) the final product must not contain more than 0.0005% THC. Otherwise this could be punished as a violation of the BTMG.
The country’s health ministry written to the Commission setting out its plans to regulate the amount of THC which can legally be in products derived from hemp and low-THC cannabis.
The ministry told the EC it intended to limit THC content to 2 mg per kg (0.0002%) for hemp seeds, hemp seed flour, and food supplements derived from hemp seed.
However, hemp seed oils can contain up to 5 mg/kg (0.0005%).
Valeo CBD oils and capsules have always fallen below the 0.0005% detection limit and can therefore be traded in Italy without any problems even after this regulation comes into force.
The result has been a proliferation of “CBD oil” preparations, as they are generally known, which claim to contain cannabidiol. However, a recent article denounced several of these products as being fraudulent and not even containing CBD. The information was taken from a report by the US Food and Drug Administration (FDA), which analysed a number of products and concluded that they contained no trace whatsoever of CBD. It is also claimed that some products are manufactured with waste from cannabis plants intended for industrial use.
These problems stem from a lack of legal definition of cannabis-derived products, giving rise to interpretations that do not match the legal position.
In this context, products containing CBD are marketed as food supplements. However, under Spanish law, food supplements can only include vitamins or minerals, not plants.
In some countries, plants can be classified as food supplements and the Spanish authorities cannot oppose the marketing of products made with medicinal plants in the EU as food supplements. In this regard, the Court of Justice handed down a categorical ruling in its judgement of 5 March, 2009 on Case C‑88/07 (Commission of the European Communities v Kingdom of Spain) on the free movement of goods and products classified as medicinal products and products lawfully produced or marketed as food supplements or dietary products in other Member States.
CBD is a substance obtained through extraction from cannabis flowers. It can also be extracted from other parts of the plant, but the flowers contain the highest proportion. CBD is not a psychotropic substance and is therefore not covered by the 1971 Vienna Convention on Psychotropic Substances, unlike tetrahydrocannabinol (THC), which is also found in cannabis flowers.
However, given that CBD production requires cannabis flowers, it is important to note that the cannabis flowers themselves are classed as “narcotic” and are subject to administrative control. Whatever its medicinal utility, cannabis cannot be said to be a traditional medicine.
Royal Legislative Decree 1/2015, of 24 July 2015, approving the consolidated text of the act on guarantees and rational use of medicine and health products refers to a list of plants whose sale to the public will be restricted or prohibited. Although the list has not yet been made public, it seems clear that it will include cannabis, since it was already on the list included in the Ministerial Order of 2004, overturned by a sentence from the Spanish High Court (Audiencia Nacional).
The International Narcotics Control Board recalls that Article 28.2 of the 1961 Convention exempting cannabis crops intended for industrial purposes applies only to seeds and fibres and not to extracts. In the case of any cannabinoids contained in the plant and intended for medicinal purposes, the same controls on cultivation need to be applied as for opium.
According to the interpretation of the 1961 Convention on Narcotic Drugs, it is clear that extraction from cannabis flowers –regardless of their THC content or whether they are male or female– is subject to control, even if the purpose of the procedure is to obtain CBD (an uncontrolled substance) and not THC (a controlled substance). The underlying question is whether extraction can be used to obtain both substances.
In Spain, the cultivation of cannabis, regardless of THC percentage, intended for the production of flowers for extraction of any cannabinoid requires prior authorisation from the Spanish drugs and health products agency (AEMPS).
The AEMPS is aware of recent developments in the therapeutic use of cannabis, with the European Medicines Agency approving a number of applications for developing medicines with CBD for treating rare diseases, such as Dravet’s syndrome, perinatal asphyxia and glioma. Arising out of this approval, pharmaceutical companies can benefit from EU incentives for medicine development, such as reduced costs and protection from competition once the medicine has been marketed.
The AEMPS has therefore authorised a number of companies in Spain to grow cannabis for research purposes and to produce derivatives from cannabis extraction. One such firm has been authorised by the AEMPS to undertake an experimental project for “Production of flowers and leaves for the extraction of cannabinoids”. The AEMPS lists a series of prerequisites for cultivation: inter alia, the company may only send the products to other AEMPS-authorised organisations and its inspection department must be able to perform controls on the plants when so required.
Legal marketing of products with CBD in Spain is close to becoming a reality; all that is lacking is the involvement of the pharmaceutical industry in marketing of the products. On completion of the experimentation phase, the problem is to find companies that have the necessary machinery and are authorised by the Health Ministry.
For the time being, there are a number of products manufactured in other EU countries which benefit from the principle of free movement of goods. The EU member states that regulate cannabis as a food supplement are Germany, the United Kingdom, Belgium, Netherlands, Italy, and the Czech Republic.
Products manufactured in Spain do not have the necessary government authorisation and therefore cannot be sold openly on the market; instead they circulate in closed circuits or over the Internet. Given that they do not contain any controlled psychotropic substance, buyers are not breaking any law. However, these products do not offer even the most minimal guarantees with regard to their exact composition, meaning that users do not know what exactly they are and what real effects they may have.
Products manufactured by Valeo Laboratories are registered in Germany as dietary supplements and can therefore be marketed under the ValeoCare label in Europe without any problems and therefore of course in Spain.
Extraction / manufacture
No specific rules have been developed regarding extraction and manufacture of CBD. However, the OGYEI paper on CBD makes an inference about the use of hemp seeds for CBD extraction. We are quite sceptical as to what this means in practice since CBD extraction from hemp seeds is not very efficient, and all relevant the authorities avoid providing any interpretation. When it comes to topical products, Cosmetic Regulation No. EC 1223/2009 prohibits the use of cannabis flowers and fruiting tops from which the resin has not been extracted.
Import / export
As CBD is not under specific government control, its import and export should not entail any special requirements.
Pure CBD isolate / flowers
Flowers may not be used for CBD extraction for use in cosmetics (Regulation (EC) No. 1223/2009) or food products (Regulation (EC) No. 178/2002). However, it is not clear to what extent this is enforced. Hungarian national regulation does not provide any information on this issue.
According to the OGYEI CBD paper, THC content in finished product should be limited to:
10 mg/kg (0.001%) in hemp seed oil in food supplements
0.2 mg/kg (0.00002%) in other hemp seed derivatives in food supplements
up to 5-10 ppm (0.0005% – 0.001%) in cosmetics
There are no provisions limiting THC in e-liquid, however in our view they should be THC-free.
CBD food supplements are allowed on the Hungarian market. There is no regulation of CBD origin, so based solely on the OGYEI CBD paper we can infer that CBD can be extracted only from hemp seeds. The paper does not specifically ban extraction of CBD from other parts of the plant, but it does say that only hemp seeds can be used in the manufacture of food supplements. We believe the process of CBD extraction for use in food supplements would be considered to be manufacturing and therefore prohibited.
Maximum level of CBD in the final product is also unregulated; however, it seems the authorities consider that naturally occurring CBD in hemp seed can reach a maximum of 25mg/kg (0.0025%). Any concentration above this would be considered enriched, and therefore come the under category of novel food.
All dietary supplements, including those with CBD, must be registered with OGYEI before they are placed on the market. If the product has been available on the EEA (European Economic Area) market, the manufacturer or importer should note where the initial registration was made and submit the information initially provided to OGYEI. These details can be submitted in either Hungarian or English.
In addition, a data sheet – available in the Dietary Supplement Act, Annex 4 – should be submitted. The data sheet requires the following data to be disclosed:
Company information – name, contact information
Country of production, manufacturer name and contact information, markets where the product is available
When the product was placed on the Hungarian and EEA market
Composition, presented in descending order
Sensory attributes (colour, taste, fragrance, shape etc)
Label (to attach)
If imported, importer’s declaration if marketed in the country of production
Instructions for use
Name, production/expiry date.
The authority may request additional information. The manufacturer or importer should try to describe the components as accurately as possible and indicate the origin of CBD – where it was extracted from.
OGYEI confirms that hemp foods with “a higher amount” of CBD fall under Regulation 2015/2283 on novel food. However, the paper does not specify what is considered to be “a higher amount”. Referring to “hemp association data”, it says that naturally occurring CBD in hemp seed oil can reach a maximum of 25 mg/kg and everything above this content is considered enriched and cannot be legally marketed as food. This is a very low CBD content, which in practice means that all edibles with more than 0.0025% CBD have to obtain novel food authorisation before they are placed on the market.
In 2018, the European Commission requested information from EU member states about the use of other hemp parts (leaves, flowers, extracts of different plant parts etc) prior to 15th May 1997. If it is proven that food from other hemp parts was legally placed on the market, the list of novel foods will be updated.
All cosmetic products placed on the EU market must comply with the Cosmetic Regulation No. EC 1223/2009, which prohibits the use of cannabis flowers and fruiting tops from which the resin has not been extracted.
The ban is a consequence of the Single convention on narcotic drugs, Annex II no. 306, according to which cannabis is defined as the flowering or fruiting tops of the cannabis plant (excluding the seeds and leaves when not accompanied by the tops) from which the resin has not been extracted.
The EU CosIng – Inventory of Ingredients lists cannabidiol under restricted substances, referring to the same schedule, which is why it is possible that CBD extracted from flowers and fruiting tops cannot be commercialised in Hungary.
All cosmetic products must be registered online free-of-charge through the EC Cosmetic Products Notification Portal (CPNP). The act of registration does not mean that the product is compliant or safe. There is no need for a separate national registration of the product.
The OGYEI paper states that safe content of THC from hemp seed in cosmetics is less than 5-10 ppm.
The Cosmetics Act gives OGYEI authority over cosmetic products on the market, while enforcement is carried out by the district office for public health and consumer protection authority.
According to the TNRSG (Tobacco and Nonsmoker Protection Act), vegetable smoking products are subject to the statutory reporting and labelling obligations. Before a product is placed on the market or the composition of a product changes, all ingredients must be reported to the BMASGK.
It is imperative to comply with the THC value regulated in the Narcotic Drugs Act, which must not exceed the limit of 0.3% (the substance that is prohibited under the Narcotic Drugs Act and has the intoxicating known effect). In the context of tobacco law, this value must also be interpreted as meaning that the THC content is only considered to be lower if the THC content does not exceed 0.3% even after conversion of THCa into THC in the course of the combustion process.